Anti-CD19 [BU12]

Absolute Antibody

Anti-CD19 [BU12]

7

BU12 reacts specifically with CD19.

BU12 has been found to inhibit specific antibody responses by tonsillar mononuclear cells to influenza virus, and IgG secretion by B lymphoblastoid cell line stimulated with IL-6 (Callard 1992). BU12 has also been used in FACS and radio-iodinated antibody binding studies to determine the levels of CD19 expression on the surface of Ramos and NALM-6 cells (Flavell 2006).

Flow Cytometry, ImmunoPrecipitation, ImmunoHistoChemistry

FC; IHC; IP; Therapeutic (block)

Research Use Only

Monoclonal

BU12

CD19

CD19 molecule

B4; B-lymphocyte antigen CD19; B-lymphocyte surface antigen B4; CVID3; differentiation antigen CD19; T-cell surface antigen Leu-12

Human

IgG1

B-lymphocyte antigen CD19

This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques.

Human

Human

The anti-CD19 antibody-producing hybridoma clone BU-12 was produced by the immunisation of two BALB/c mice with the Burkitt's lymphoma cell line EB4. Immune spleen cells from these animals were fused with the mouse X63 AG8 653 plasmacytoma cell line and resulting hybridomas selected in HAT medium. Screening of hybridoma culture supernatants on a range of T-, B-, myeloid and erythroid cell lines and on sections of normal human tonsil led to the selection of the pan-B-cell-reactive BU-12 hybridoma clone.

-20°C,2°C to 8°C

12352203